Browsing Tag
neurofibromatosis type 1
2 posts
Pasithea Therapeutics raises $60m in discounted public offering as biotech funding momentum returns
Find out how Pasithea Therapeutics’ $60 million stock offering reshapes its clinical runway, dilution outlook, and investor sentiment.
Pasithea Therapeutics advances cancer trial after positive safety review of PAS-004
Pasithea Therapeutics Corp. (NASDAQ: KTTA) has reached a significant milestone in its Phase 1 clinical trial of PAS-004,…